The Mayo Clinic will offer Exact Sciences ' ( EXAS +4.8% ) Cologuard as a screen for colorectal cancer. The test will be available to patients through their primary care physicians. It is the first health system to sign on to offer the test. Post your comment!
By Andy Batts : Exact Sciences (NASDAQ: EXAS ) has bagged FDA approval for ..... colorectal cancer. Upon approval, Exact Sciences instantly received a proposed ..... healthcare providers for $599. Exact Sciences CEO Kevin Conroy told FierceMedicalDevices
Gainers: ICPT +45% . FRF +40% . INSY +15% . SUPN +14% . EXAS +8% . CNAT +8% . ARTX +6% . Losers: DNDN -23% . GALE -12% . CALL -10% . NUAN -9% . TKMR -8% . FLO -8% . HCLP -5% . Post your comment!
* U.S. Food and Drug Administration has approved Exact Sciences ' cologuard stool-DNA-based, non-invasive colorectal cancer screening test
The FDA clears Exact Sciences ' ( EXAS +2.5% ) Cologuard , a stool-based colorectal screening test ..... proposes to cover the cost of the test once every three years. EXAS shares are up 4% AH on average volume. Post your comment!
By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little
CFA : For a modestly-sized diagnostics stock, Exact Sciences (NASDAQ: EXAS ) seems to generate an above-average level of ..... and I continue to believe that is the case with Exact Sciences . My thesis in brief - the Cologuard works, is
EXACT Sciences Corporation (NASDAQ: EXAS ) Q2 2014 Earnings Conference Call July 22, 2014 10:00 AM ET Executives Rod Hise ..... Operator Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call. At this time
Exact Sciences (NASDAQ: EXAS ) Q2 results : Revenues: $0; R&D Expense: $7.2M (+11.1%); SG&A Expense: $12.4M (+78.9%); Operating
Exact Sciences (NASDAQ: EXAS ): Q2 EPS of -$0.24 in-line. Press Release Post your comment!